Darzalex Faspro
FDA Approves Darzalex Faspro With Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma
The FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Research & Development LLC) ...
JULY 31, 2024
FDA Approves Darzalex Faspro Plus Kd for RR Multiple Myeloma
The FDA approved daratumumab plus hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech) in combination with ...
DECEMBER 3, 2021
FDA Approves Darzalex Faspro With Pom-Dex for Multiple Myeloma
The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen) in combination with pomalidomide and ...
JULY 14, 2021
Subcutaneous Daratumumab-Based Regimen Effective for Advanced MM
The addition of subcutaneous daratumumab to the standard combination of pomalidomide and dexamethasone (Pd) ...
FEBRUARY 23, 2021
FDA Grants New Indication for Darzalex Faspro: Newly Diagnosed Light Chain Amyloidosis
The FDA granted a new indication for daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen) used with ...
JANUARY 21, 2021
